Anika Therapeutics (NSDQ:ANIK) touted data today from a Phase III trial for its Cingal hyaluronic acid-corticosteroid combination viscosupplement as a treatment for osteoarthritis-related knee pain.
The data showed that treatment with Cingal yielded better immediate and short-term pain relief compared to hyaluronic acid alone and better pain and stiffness relief through 26 weeks compared to saline. The data was published in the journal Cartilage.
Get the full story at our sister site, Drug Delivery Business News.
The post Anika touts Phase III data for Cingal knee therapy appeared first on MassDevice.